Physician profile
Chun Hong
NPI 1003844960
$8,208.76
in general payments reported to CMS, 2019-2025
41 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $913 · 2021: $1,115 · 2022: $1,057 · 2023: $1,179 · 2024: $1,091 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,738.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,419.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.40 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $633.83 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $514.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $509.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $504.00 | 2019-2022 | |
| Pfizer INC. | $494.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $419.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $386.69 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $315.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $277.22 | 2019-2025 | |
| Inspire Medical Systems, INC. | $196.38 | 2023-2025 | Inspire |
| Amarin Pharma, INC. | $190.65 | 2019-2022 | |
| Esperion Therapeutics, INC. | $168.47 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $148.48 | 2023-2025 | Gemtesa |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $144.42 | 2021-2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $134.93 | 2022 | |
| Qorumpartners | $107.38 | 2022 | |
| Allergan, INC. | $94.89 | 2019-2021 | |
| Bausch Health US, LLC | $83.49 | 2024-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $80.28 | 2023 | Quviviq |
| Corcept Therapeutics | $73.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $71.12 | 2024-2025 | Rexulti |
| Gilead Sciences, INC. | $68.75 | 2019-2022 | |
| Exact Sciences Corporation | $61.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $58.74 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $43.38 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Seqirus USA INC | $34.31 | 2024-2025 | Fluad, Flucelvax |
| Genentech USA, INC. | $33.37 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $31.91 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.84 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.63 | 2019 | |
| Tanabe Pharma America, INC. | $25.72 | 2024 | |
| Medtronic Minimed, INC. | $22.05 | 2019 | |
| Antares Pharma, INC. | $19.93 | 2022 | |
| Zealand Pharma US, INC. | $18.42 | 2021 | |
| Lundbeck LLC | $16.93 | 2024 | Rexulti |
| Insulet Corporation | $14.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.